Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04367883

Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection

Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection.

Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease.

The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Covid19 ACE Inhibitors ARB Amantadine Antihistamine Allergy COVID-19 Coronaviridae Infections Coronavirus Infections Infections Influenza Vaccination Influenza, Human Lung Diseases Nidovirales Infections Orthomyxoviridae Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital de Terrassa

Terrassa, Barcelona, 08227, Spain

Location status: Recruiting

Location contact

Anna Puigdellívol-Sánchez, Ph.D.

CONTACT

[email protected]

34-93-5884555

About this study

The number COVID cases would be related to hospital admissions. Among hospital admissions, the number of previous treatments, the length of admission, the need or not of the Intensive Care Unit (ICU) and their final status (survivors or non survivors) would be studied.

If patients that previously received the influenza vaccine or treated with ACEI, ARB, antihistamines or amantadine showed a better evolution, it would be proposed to extend vaccination and the inclusion of ACE inhibitors, ARB, antihistamines or amantadine in the treatment of infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause.

Exclusion criteria

  • None.
  • For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.

Treatment and study plan

Antihistamine

Drug

No intervention is performed. We propose an observational study.

Other names: Antihistamines for COVID

Amantadine

Drug

No intervention is performed. We propose an observational study

Other names: Amantadine for COVID

ACEI

Drug

No intervention is performed. We propose an observational study.

Other names: ACEI and COVID

ARB

Drug

No intervention is performed. We propose an observational study.

Other names: ARB and COVID

Influenza vaccine and COVID

Other

No intervention is performed. We propose an observational study.

Primary outcomes

  1. hospital output

    Time frame: from March 1, 2020.

    exitus vs hospital output

Secondary outcomes

  1. hospital stay

    Time frame: From March 1, 2020.

    length of the hospital stay

Study contacts

Contact information is provided by the study sponsor or research team.

Anna Puigdellívol-Sánchez, Ph.D.

CONTACT

[email protected]

34-93-5884555

Mar Muñoz

CONTACT

[email protected]

34-93-7003657 ext. 1895

Sponsors and collaborators

Lead sponsor

Consorci Sanitari de Terrassa

Other

Collaborators

  • Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
  • Institut Català de la Salut

Registry information

Official study title

Evaluation of Influenza Vaccination and Treatment With ACEI and ARB in the Evolution of SARS-CoV2 Infection

Important dates

Study start
2020
Primary completion
2025
Study completion
2028
First posted
Apr 29, 2020
Registry last updated
Mar 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.